Hledání článků
Filtry
Fellström, BC, Jardine, AG, Schmieder, RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395–1407.
Bouchard J, Madore F. Role of citrate and other methods of anticoagulation in patiens with severe liver failure requiring continuous renal replacement therapy. Nephrol Dial Transplant Plus 2009;2:11–19.
Lins RL, Elseviers MM, Van der Niepen P, Hoste E, Malbrain ML, Damas P, Devriendt J, for the SHARF investigators. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of randomized clinical trial. Nephrol Dial Transpl2009; 24:512–518.
Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589–596.
Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E; Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecined’Urgence des Hôpitaux extra-Universitaires. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009;37:803–810.
Hilgers KF, Mann FE. The choice of antihypertensive therapy in patients with the metabolic syndrome – time to change recommendations? Nephrol Dial Transplant 2008;23:3389–3391.
Obermayr RP, Temml Ch, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19,2407–2413.
Okša A, Spustová V, Krivošíková Z, Gazdíková K, Fedelešová V, Lajdová I, Štefíková K, Bernasovská G, Žilinská Z, Dzúrik R. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008;31:322–329.
Quintana LF, Gonzales AS, Kalko SG, Bañon-Maneus E, Sole M, Diekman F, Gutierrez-Dalma A, Abian J, Campistol JM. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009;20:428–435.
Schena FP, Pascoe MD, Alberu J, Carmen Rial del M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Dolinsky M, Goldber-Albers R, LI H, Scarola J, Neylan JF, for the Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-months efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233–242.
Mendelssohn DC, Mujais SK, Soroka SD, Brouillette J, Takano T, Barre PE, Mittal BV, Singh A, Firanek C, Story K, Finkelstein FO. A prospective evaluation of renal replacement therapy modality eligibility. Nephrol Dial Transplant 2009;24:555–561.
Bradbury BD, Critchlow CW, Weir M et al. Impact of elevated C-reactive protein levels on erythropoiesis – stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009;24:919–925.